Endra Life Sciences Form 144 Filing Signals Potential $3.4M Insider Sale
1h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
form-144insider-selling
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
A Form 144 filing for Endra Life Sciences Inc. was submitted to the SEC on June 25, 2026, according to a disclosure published by investing.com. The notice of proposed sale indicates the company's Chief Financial Officer intends to sell up to 3.25 million shares of common stock. Based on the stock's recent closing price near $1.05, the potential sale represents approximately $3.4 million in value. The filing highlights renewed liquidity concerns for a development-stage medical device firm that has seen its share price decline over 60% in the past year.
Form 144 filings signal an insider's intent to sell shares pursuant to Rule 144 of the Securities Act, typically after holding restricted securities for a minimum period. Historical comparables show significant insider selling often precedes periods of heightened stock volatility. For instance, a 4.5 million share Form 144 sale by a peer in the ultrasound space, Butterfly Network Inc., in January 2025 preceded a 25% share price decline over the subsequent quarter.
The current macro backdrop presents a challenging environment for cash-burning healthcare startups. The 10-year Treasury yield has remained elevated above 4.5% for most of the second quarter, compressing valuations for firms with distant profitability horizons. The Federal Reserve's June FOMC meeting projected only a single rate cut for 2026, delaying relief for capital-intensive sectors.
This specific event was likely triggered by the expiration of mandatory holding periods for the CFO's shares, potentially tied to stock-based compensation. The filing coincides with a pivotal period for Endra, which is conducting final validation studies for its lead Thermo Acoustic Enhanced UltraSound device. The firm reported cash and equivalents of $7.8 million as of its last quarterly statement, raising questions about its runway.
The filing specifies a proposed sale of exactly 3,250,000 shares of Endra Life Sciences common stock. The company's stock closed at $1.04 per share on June 24, the trading day prior to the filing's publication. The indicated sale volume amounts to roughly 4.2% of Endra's public float, estimated at 77.5 million shares. Endra's market capitalization stands at approximately $80.6 million.
A before/after comparison underscores the stock's recent pressure. The share price has fallen from a 52-week high of $3.10, representing a 66% decline. Year-to-date, Endra's stock is down 48%, significantly underperforming the iShares Biotechnology ETF, which is down 12% over the same period. The stock trades 92% below its all-time high of $13.75 reached in late 2022.
Insider selling activity across the broader small-cap medical device sector has increased over the past quarter. An analysis of Form 144 data from June shows an average of 12 filings per week for similar market cap firms, up from an average of 8 per week in Q1 2026. Endra's price-to-sales ratio of 4.2 is now below the peer group median of 5.8.
The sale signals potential near-term technical headwinds for Endra's stock as the market absorbs the additional supply. The filing's size relative to average daily trading volume, which is about 1.1 million shares, suggests the transaction could take several sessions to complete, weighing on the price. Second-order effects may extend to other micro-cap medical device developers like Sonendo, Inc. and EchoNous Inc., as investors scrutinize their insider activity and cash positions.
A key limitation of interpreting this single filing is that it represents a plan, not a completed transaction. The CFO may sell fewer shares than indicated or none at all. the sale could be for personal financial planning unrelated to company prospects, a common rationale for executive stock sales.
Positioning data from options markets shows increased put volume in Endra over the past week, with open interest concentrated at the $1.00 strike price for July expiration. Short interest as a percentage of float remains elevated at 8.5%, above the sector average of 5.1%. Flow data indicates institutional sellers have been net sellers for four consecutive weeks.
The next critical catalyst is Endra Life Sciences' scheduled second-quarter earnings report, expected in the first week of August 2026. Investors will focus on the updated cash burn rate and any commentary on the timeline for its TAEUS system's regulatory submission. The company is also slated to present at the virtual Canaccord Genuity Medical Technology & Diagnostics Forum on July 16, 2026.
Key technical levels to monitor include the $1.00 psychological support level and the 50-day simple moving average, currently at $1.28. A sustained break below $1.00 could trigger further selling pressure and increase delisting risk from the Nasdaq, which requires a minimum bid price of $1.00. On the upside, any break above the June intraday high of $1.45 would require a significant positive development.
Market focus will also remain on the broader interest rate environment, with the next Consumer Price Index report due on July 10, 2026. A resurgence in inflation data could extend the high-rate pressure on development-stage healthcare stocks, while a cooler print may provide sector-wide relief.
A Form 144 notifies the SEC that a corporate insider, officer, or major shareholder intends to sell a specific number of company shares. For retail investors, it is a required disclosure of potential future selling pressure, not a record of completed trades. The filing itself does not guarantee the sale will happen, but large filings can impact market sentiment and liquidity, especially for low-volume stocks like Endra.
The scale of the proposed sale relative to Endra's market cap and float is significantly larger than typical activity at established firms. For example, a $3.4 million sale at a firm like Intuitive Surgical or Boston Scientific would represent a minuscule fraction of their multi-billion dollar floats and rarely moves the stock. At Endra's size, the same dollar amount constitutes a material overhang, reflecting the heightened sensitivity of micro-cap stocks to insider liquidity events.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.